BELLUS Health Inc. (BLU) |
| 14.745 0.005 (0.03%) 06-28 15:59 |
| Open: | 14.74 |
| High: | 14.75 |
| Low: | 14.74 |
| Volume: | 2,839,350 |
| Market Cap: | 1,870(M) |
| PE Ratio: | -20.2 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 17.24 |
| Resistance 1: | 14.76 |
| Pivot price: | 14.71 |
| Support 1: | 14.53 |
| Support 2: | 14.39 |
| 52w High: | 14.76 |
| 52w Low: | 6.38 |
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
Financials
| EPS | -89990000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -602.00 |
| Return on Assets (ttm) | 46.7 |
| Return on Equity (ttm) | -16.7 |
Company news
Fri, 16 Jun 2023
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders - Business Wire
Tue, 16 May 2023
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition - Business Wire
Fri, 12 May 2023
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights - Business Wire
Thu, 20 Apr 2023
Bellus Health shareholders should take the deal, says Research Capital - Cantech Letter
Tue, 18 Apr 2023
Bellus’ stock surges as GSK coughs up $2B for an acquisition - BioWorld MedTech
Tue, 18 Apr 2023
GSK bets $2 bln on Bellus cough drug to soothe pipeline fears - Reuters
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
